ERNEST HAWK to Cardiovascular Diseases
This is a "connection" page, showing publications ERNEST HAWK has written about Cardiovascular Diseases.
Connection Strength
0.162
-
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4):310-21.
Score: 0.032
-
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13.
Score: 0.030
-
Statins and cancer prevention. Nat Rev Cancer. 2005 Dec; 5(12):930-42.
Score: 0.026
-
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17; 352(11):1071-80.
Score: 0.024
-
Primary cancer prevention trials. Hematol Oncol Clin North Am. 2000 Aug; 14(4):809-30.
Score: 0.018
-
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug; 4(8):1172-80.
Score: 0.009
-
Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2010 May; 3(5):588-96.
Score: 0.009
-
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 05; 114(10):1028-35.
Score: 0.007
-
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84.
Score: 0.007